Filing Details

Accession Number:
0001493152-23-036581
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-06 18:43:55
Reporting Period:
2023-10-04
Accepted Time:
2023-10-06 18:43:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1725430 Intelligent Bio Solutions Inc. INBS Surgical & Medical Instruments & Apparatus (3841) 821512711
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1830957 Kevin Spiro Sakiris C/O Intelligent Bio Solutions Inc.,
142 West 57Th Street, 11Th Floor
New York NY 10019
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-04 112,727 $0.00 117,427 No 4 P Indirect Held by Anest Holdings Pty Ltd
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Held by Anest Holdings Pty Ltd
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrants (Series E) Acquisiton 2023-10-04 112,727 $0.00 112,727 $0.00
Common Stock Common Stock Warrants (Series F) Acquisiton 2023-10-04 112,727 $0.00 112,727 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
112,727 2029-04-04 No 4 P Indirect
112,727 2025-04-04 No 4 P Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,765 Direct
Footnotes
  1. The reported securities are included within 112,727 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").
  2. The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.
  3. The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).
  4. These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.